Cargando…

Clinical analysis of severe COVID-19 patients

BACKGROUND: Patients with unexplained pneumonia appeared in Wuhan, Hubei Province at the end of 2019. OBJECTIVE: To analyze the clinical data of patients with severe COVID-19. METHODS: Medical records of 28 severe patients admitted to the intensive care unit of Wuhan Xinzhou District People’s Hospit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao, Sun, Bin, Li, Xiayuan, Wang, Yun, Yang, Zhengping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028659/
https://www.ncbi.nlm.nih.gov/pubmed/35124599
http://dx.doi.org/10.3233/THC-228021
_version_ 1784691676661415936
author Wang, Hao
Sun, Bin
Li, Xiayuan
Wang, Yun
Yang, Zhengping
author_facet Wang, Hao
Sun, Bin
Li, Xiayuan
Wang, Yun
Yang, Zhengping
author_sort Wang, Hao
collection PubMed
description BACKGROUND: Patients with unexplained pneumonia appeared in Wuhan, Hubei Province at the end of 2019. OBJECTIVE: To analyze the clinical data of patients with severe COVID-19. METHODS: Medical records of 28 severe patients admitted to the intensive care unit of Wuhan Xinzhou District People’s Hospital were collected from January 31 to March 17. RESULTS: The mortality rate of severe patients in our study was 39.3%. There were statistically significant differences in age, admission systolic blood pressure, lymphocyte count, albumin, total bilirubin, and lactate dehydrogenase between the death group and the survival group ([Formula: see text] 0.05). There were statistically significant differences in APACHE II, CURB-65, SOFA, respiratory frequency, systolic pressure, platelet, procalcitonin, albumin, creatinine, creatine kinase isoenzyme, lactate dehydrogenase, chloride ion, prothrombin time, international normalized ratio, arterial partial pressure of oxygen, and FiO2 at ICU between the death group and the survival group ([Formula: see text] 0.05). CONCLUSIONS: Fever and cough are the main symptoms, which is useful for predicting the prognosis to dynamically measure the APACHE II, CURB-65, SOFA, respiratory frequency, lymphocyte count, platelet, lactate dehydrogenase, and coagulation tests. The drugs that protect the liver and heart may improve the survival rate of patients with severe COVID-19.
format Online
Article
Text
id pubmed-9028659
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-90286592022-05-06 Clinical analysis of severe COVID-19 patients Wang, Hao Sun, Bin Li, Xiayuan Wang, Yun Yang, Zhengping Technol Health Care Research Article BACKGROUND: Patients with unexplained pneumonia appeared in Wuhan, Hubei Province at the end of 2019. OBJECTIVE: To analyze the clinical data of patients with severe COVID-19. METHODS: Medical records of 28 severe patients admitted to the intensive care unit of Wuhan Xinzhou District People’s Hospital were collected from January 31 to March 17. RESULTS: The mortality rate of severe patients in our study was 39.3%. There were statistically significant differences in age, admission systolic blood pressure, lymphocyte count, albumin, total bilirubin, and lactate dehydrogenase between the death group and the survival group ([Formula: see text] 0.05). There were statistically significant differences in APACHE II, CURB-65, SOFA, respiratory frequency, systolic pressure, platelet, procalcitonin, albumin, creatinine, creatine kinase isoenzyme, lactate dehydrogenase, chloride ion, prothrombin time, international normalized ratio, arterial partial pressure of oxygen, and FiO2 at ICU between the death group and the survival group ([Formula: see text] 0.05). CONCLUSIONS: Fever and cough are the main symptoms, which is useful for predicting the prognosis to dynamically measure the APACHE II, CURB-65, SOFA, respiratory frequency, lymphocyte count, platelet, lactate dehydrogenase, and coagulation tests. The drugs that protect the liver and heart may improve the survival rate of patients with severe COVID-19. IOS Press 2022-02-25 /pmc/articles/PMC9028659/ /pubmed/35124599 http://dx.doi.org/10.3233/THC-228021 Text en © 2022 – The authors. Published by IOS Press. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Hao
Sun, Bin
Li, Xiayuan
Wang, Yun
Yang, Zhengping
Clinical analysis of severe COVID-19 patients
title Clinical analysis of severe COVID-19 patients
title_full Clinical analysis of severe COVID-19 patients
title_fullStr Clinical analysis of severe COVID-19 patients
title_full_unstemmed Clinical analysis of severe COVID-19 patients
title_short Clinical analysis of severe COVID-19 patients
title_sort clinical analysis of severe covid-19 patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028659/
https://www.ncbi.nlm.nih.gov/pubmed/35124599
http://dx.doi.org/10.3233/THC-228021
work_keys_str_mv AT wanghao clinicalanalysisofseverecovid19patients
AT sunbin clinicalanalysisofseverecovid19patients
AT lixiayuan clinicalanalysisofseverecovid19patients
AT wangyun clinicalanalysisofseverecovid19patients
AT yangzhengping clinicalanalysisofseverecovid19patients